Daniel Nevrivy, PH.D.,Attorney,Nevrivy Patent Law Group P.L.L.C to Speak at the Knowledge Group's The BPCIA Patent Dance-What Biosimilar Companies Need To Know
This event is scheduled for January 10, 2017 from 3:00pm.
- (1888PressRelease) December 29, 2016 - The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Daniel J. Nevrivy, PH.D., Attorney, Nevrivy Patent Law Group P.L.L.C will speak at the Knowledge Group's webcast entitled: "BPCIA Patent Dance - What Biosimilar Companies Need To Know LIVE Webcast."
For further details, please visit:
https://theknowledgegroup.org/event-homepage/?event_id=2114
About Daniel J. Nevrivy
Dr. Nevrivy is a patent attorney specializing in biotechnology and pharmaceutical patent law. His practice includes drafting and prosecuting domestic and international patent applications, counseling clients regarding intellectual property strategies and portfolio management, freedom to operate, due diligence, patentability, invalidity and noninfringement. In particular, he has significant experience helping companies navigate the complex patent issues associated with the development and launch of proprietary products.
About Nevrivy Patent Law Group P.L.L.C
Nevrivy Patent Law Group P.L.L.C. is an intellectual property (IP) law firm located in Washington, D.C. The firm is committed to providing clients with the highest quality legal representation that is responsive, cost-effective, and aligned with their business goals.
The firm's attorneys have extensive experience in IP law and a very high level of technical competence and scientific knowledge. The firm's client base and experience enable it to appreciate the unique issues that each client faces and to tailor the representation to suit their business and technical needs. The firm's clients are located throughout the U.S. and internationally and include inventors, start-ups, emerging growth and mid-size companies, Fortune 500 firms and leading research universities.
Technology areas of focus include biologics, pharmaceutical formulations, chemicals, chemical syntheses and processes, fuel cells, drug discovery, beverages and food science, polymers, agrochemicals, pigments, paper products, oil/gas refinery technologies, energy, pharmaceuticals and drug delivery technologies, stem cells and regenerative medicine, diagnostics and personalized medicine, molecular biology, biochemistry, vaccines, microbiology, antibodies, therapeutic methods, consumer products, mechanical devices, veterinary medicine, genomics, inflammation, cancer, small molecules, organic chemicals, optics, semiconductors, advanced materials, nanotechnology and nanobiotechnology.
Event Synopsis:
For about seven years now, the Biologics Price Competition and Innovation Act ("BPCIA") of 2009 has continually facilitated entry of biosimilar products into the market. By allowing submission of an abbreviated Biologics License Application ("aBLA") to an already approved and licensed FDA product, BPCIA aids in making the pioneer and the applicant meet halfway. However, meeting halfway is not as easy as it sounds. There are matters to deal with: agreements and disclosures to be settled down before the commercial marketing of a biosimilar product begins. Patent disputes are among the most debated, and often controversial issues that biosimilar companies are faced with.
In its second part, BPCIA addresses certain patent resolution issues. Commonly called as the "patent dance", 42 U.S.C. § 262(l) provides the steps and schedule when a reference sponsor product and a biosimilar applicant exchange "confidential information" about the aBLA. Typically, the confidential information disclosed by the applicant is its application and manufacturing trade secrets.
Indeed, the music hasn't stopped for biosimilar companies, and "patent dance" is still obviously becoming a dance craze for them. Questions remain as to whether or not companies facing the "dance" will minimize the potential for litigation under the BPCIA, and to what extent will this craze bring the industry.
The Knowledge Group has assembled a panel of key thought leaders to provide the audience with an in-depth analysis of the BPCIA "Patent Dance" and its recent developments. In this two-hour LIVE Webcast, a panel of distinguished professionals and thought leaders will help biosimilar companies understand the important aspects of this significant topic. Speakers will also offer best practices in helping the audience better understand the steps and legal issues brought by the latest litigations.
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam